Daily6d
Centers for Disease Control and Prevention (CDC) Lowers Pneumococcal Vaccination Age to 50
Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...
Hosted on MSN5d
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
Simmons: Vaccination 'single most powerful intervention'
Dr. Matthew Simmons, UPMC Western Maryland vice president of medical staff affairs, said vaccines provide the "single most powerful intervention" that have saved lives. He recently discussed the ...
Medscape11d
EMA Recommends Approval of Capvaxive Pneumococcal Vaccine
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...
Hosted on MSN8d
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...
The Meadville Tribune7d
Doctor touts benefits of vaccinations
Dr. Matthew Simmons, UPMC Western Maryland vice president of medical staff affairs, said vaccines provide the “single most ...
McKnight's Long-Term Care News5d
‘Vaccine fatigue’ could be a common LTC theme in 2025
Many nursing home residents are refusing COVID shots this winter, though flu vaccine penetration has remained strong historically.
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...